Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Candice Brady

Foot and Ankle Surgery Camarillo, CA Doctor of Osteopathy

NPI 1124368667 CMS profile 1398525

400 Camarillo Ranch Rd Ste 101, Camarillo, CA 93012

Open in the dashboard

General payments

$461,841

873 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Candice Brady of Camarillo, CA is reported in the CMS Open Payments database as having received $461,841 across 873 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $86,280 117
2024 General $101,269 161
2023 General $138,860 256
2022 General $120,505 192
2021 General $5,863 72
2020 General $3,252 45
2019 General $5,811 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Candice Brady
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Candice Brady were reported at $86,280. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Candice Brady Foot and Ankle Surgery median Middle half National median
2019 $5,811 $1,327 $279–$5,421 $163
2020 $3,252 $795 $121–$3,473 $114
2021 $5,863 $1,289 $201–$4,963 $132
2022 $120,505 $1,539 $270–$6,067 $149
2023 $138,860 $1,117 $257–$5,264 $160
2024 $101,269 $1,064 $235–$4,944 $164
2025 $86,280 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $443,321 694 payments
  2. Arthrex, Inc. $4,059 17 payments
  3. Ucb SA $2,760 1 payment
  4. Treace Medical Concepts, Inc. $2,112 15 payments
  5. Life Spine, Inc. $1,430 9 payments
  6. Micromed Inc $1,200 1 payment
  7. Nexus Spine, LLC $1,151 3 payments
  8. Novo Nordisk Inc $619 23 payments
  9. UCB, Inc. $590 6 payments
  10. Abbott Laboratories $555 4 payments
  11. Other $4,044 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $330,035 180 payments
  2. Travel and Lodging $101,499 272 payments
  3. Food and Beverage $22,805 367 payments
  4. Education $4,741 53 payments
  5. Consulting Fee $2,760 1 payment
Products named General payments · program years 2019–2025
  1. EVENITY $364,949 535 payments
  2. Prolia $73,703 185 payments
  3. Lapiplasty System $2,033 13 payments
  4. AVATAR MINIMALLY INVASIVE SPINAL SYSTEM $1,159 6 payments
  5. PRO-LINK STAND-ALONE CERVICAL SPACER SYSTEM $1,159 6 payments
  6. ProLIft $1,140 7 payments
  7. TruLift $1,019 5 payments
  8. Tymlos $421 33 payments
  9. Wegovy $379 10 payments
  10. Proclaim Family of SCS IPGs $302 2 payments
  11. Other $4,077 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

280

Median for Orthopedic Surgery: 203

Drug cost

$261,644

Median for Orthopedic Surgery: $1,433

Branded share of claims

44.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tymlos Abaloparatide Brand 52 $140,971
Evenity (2 Syringes) Romosozumab-Aqqg Brand 31 $73,352
Prolia Denosumab Brand 29 $45,967
Ibandronate Sodium Generic 32 $918
Risedronate Sodium Generic 13 $153
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $148
Meloxicam Generic 110 $135

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$623,870

Of which drugs: $556,102

Medicare patients

157

Average age 75

Services billed

59,491

124 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Osteoporosis 75%
High blood pressure 67%
Arthritis 64%
Depression 32%
Ischemic heart disease 27%
Diabetes 23%
Chronic kidney disease 18%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, romosozumab-aqqg, 1 mg J3111 Office 42 53,341 $455,543
Injection, denosumab, 1 mg J0897 Office 50 4,860 $100,432
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 156 $118

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $98,041
$98,041 31 53,341
Prolia
  • Amgen Inc. $2,860
$2,860 29 4,860
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $102
$102 — —
QULIPTA
  • AbbVie, Inc. $91
$91 — —
Wegovy
  • Novo Nordisk Inc $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

873 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record